LongevityBank

What LongevityBank does

LongevityBank (branded as iPSCbank) is a Singapore-based cell banking platform and wholly-owned subsidiary of CytoMed Therapeutics Limited (NASDAQ: GDTC). The company was launched in September 2024 following CytoMed's acquisition of a licensed Malaysian cord blood bank, with operations across Singapore (registered office) and Malaysia (GMP facility, laboratory, and corporate entity IPSC Depository Sdn Bhd). Its core offering is autologous cell preservation for two primary segments: expectant parents banking umbilical cord blood and cord tissue (MSCs) at birth, and health-conscious adults banking peripheral blood mononuclear cells (PBMCs) for future conversion into iPSCs or cancer-killing immune cells.

The technology stack centers on a GMP-compliant manufacturing facility built to Malaysian NPRA/PIC/S standards with a NEBB-certified Grade A clean room, supporting isolation, processing, and cryopreservation of cord blood stem cells, mesenchymal stem cells, peripheral blood mononuclear cells, and induced pluripotent stem cells. The company's principal technical differentiator is a global exclusive patent portfolio covering reprogramming of banked cells into CAR-grafted gamma delta T (CAR-gdT) cells and iPSCs, plus granted patents on γδ NKT generation. This positions the bank not merely as a storage service but as feedstock for CytoMed's parent-level clinical pipeline, including the ANGELICA trial at National University Hospital (Singapore).

LongevityBank operates a direct-to-consumer subscription model. Cord blood pricing (RM 300 enrollment plus RM 150-1,200 annual storage depending on CBU count) is the only publicly disclosed tier; PBMC, iPSC, and MSC banking pricing is not posted. Distribution combines baby expo sales (e.g., TCE Baby Expo), a five-platform social media presence, clinic/hospital collection partnerships for PBMC draws, and content marketing. Capital base to date is modest, anchored by a US$500,000 non-dilutive investment from ICH Capital in November 2025 earmarked for operations and China regulatory development.

Name

LongevityBank

Legal name

LongevityBank Pte Ltd

Website

https://ipscbank.sg

Company type

Private

Founded year

2024

Operating status

Operating

Short description

LongevityBank (iPSCbank) is a Singapore-based autologous cell banking subsidiary of CytoMed Therapeutics (NASDAQ: GDTC), offering cord blood, MSC, PBMC, and iPSC cryopreservation through a GMP/PIC/S-compliant Malaysian facility, serving expectant parents and health-conscious adults in Southeast Asia.

Ownership category

akta.pro rank

Product category

Stem Cell Banking Services

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

akta.pro secondary industries

Cell Therapy Developers (Autologous) (HLAAABAA), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

Keywords

• Cell banking services
• Cord blood banking
• Stem cell cryopreservation
• Autologous cell therapy
• IPSC banking

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Infrastructure, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Cord Blood Banking Services: One-time collection fee plus annual storage fees for umbilical cord blood stem cells. Enrollment fee of RM 300 for agreements signed after October 31, 2024, with semi-annual (RM 150-600) or annual (RM 300-1,200) payment plans depending on number of CBU units stored.
2. PBMC Banking Services: Blood collection and cryopreservation of peripheral blood mononuclear cells for future autologous therapeutic use. Revenue from collection and annual storage fees.
3. iPSC Banking Services: Conversion of blood cells into induced pluripotent stem cells and long-term cryopreservation for future regenerative medicine applications.
4. Investment Capital: Non-dilutive investment of up to US$500,000 from ICH Capital received for subsidiary LongevityBank, focusing on autologous cell-based therapies.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

LongevityBank provides autologous cell banking services, collecting and cryopreserving customers' own biological cells — including umbilical cord blood stem cells, cord tissue mesenchymal stem cells (MSCs), peripheral blood mononuclear cells (PBMCs), and induced pluripotent stem cells (iPSCs) — for future therapeutic use in cancer treatment and regenerative medicine. The cells are processed and stored at a GMP-compliant facility in Malaysia under PIC/S-aligned standards, and banked cells can be reprogrammed into proprietary cancer-killing immune cells (CAR-gdT) or iPSCs through parent CytoMed's patented technology.

Product overview

LongevityBank operates as a cell banking platform offering multiple specialized banking services for preserving various types of biological cells. The core offerings include Cord Blood Banking (umbilical cord blood stem cells), Cord Tissue MSC Banking (mesenchymal stem cells), PBMC Banking (peripheral blood mononuclear cells), and iPSC Banking (induced pluripotent stem cells). These services are provided through a GMP-certified facility and position the company as a pioneer in PBMC and iPSC banking in Southeast Asia. The platform enables customers to bank their cells for future therapeutic use, including cancer treatment and regenerative medicine applications.

Differentiator

Problem solved

Functional benefit

Products and services

• Cord Blood Banking Umbilical cord blood banking service for cryopreservation of cord blood stem cells, which can be used to treat nearly 80 diseases including blood disorders, immune system deficiencies, cancers, and tumors. Targeted at expectant parents who want to preserve their baby's cord blood for future medical use.
• Cord Tissue (MSC) Banking Mesenchymal stem cell banking service derived from cord tissue, intended for beauty and anti-aging cell therapy applications. Targeted at customers interested in regenerative and aesthetic medicine uses.
• PBMC Banking Peripheral blood mononuclear cell banking service providing a source of the customer's own immune cells for future cancer immunotherapy and regenerative medicine applications. Banked PBMCs can be reprogrammed into proprietary cancer-killing immune cells or iPSCs. Targeted at health-conscious adults.
• iPSC Banking Induced pluripotent stem cell banking service providing an unlimited source of personalized therapeutic cells. Cryopreserved PBMCs can be converted into iPSCs on request for future regenerative medicine applications, subject to regulation. Targeted at individuals interested in future access to stem cell therapies.

Quantifiable outcome

• Cord blood stem cells used in treatment of nearly 80 diseases
• +4 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• A*STAR (Agency for Science, Technology and Research)coreStrategic or Co-development PartnerCytoMed Therapeutics, parent company of LongevityBank, was spun out from A*STAR in 2018. This connection provides access to research capabilities, patented technologies, and scientific expertise developed at Singapore's premier research institute.
• National University Hospital (Singapore)coreStrategic or Co-development PartnerParent company CytoMed is conducting the ANGELICA clinical trial at National University Hospital using gamma-delta T cells to treat solid tumors and cancers resistant to standard treatments. Stored cells from LongevityBank may be utilized in future therapeutic applications.
• Cellsafe International Sdn Bhd (In Liquidation)minorOthersCellsafe International Sdn Bhd was a previous cord blood banking partner now in liquidation. LongevityBank/IPSC Depository acquired the licensed cord blood bank operations and is handling customer notifications and service transfers for former Cellsafe customers.

Scale indicators3 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Cellsafe International: Former Malaysia-based cord blood bank (now in liquidation) whose customer book was acquired by LongevityBank. Directly comparable as a historical direct competitor in Malaysian cord blood banking whose assets and customer base have been absorbed into LongevityBank.
• Cordlife Group: Singapore-listed cord blood and tissue banking operator with a regional footprint across Asia. Directly comparable as a consumer-facing autologous cell bank in the same geographies (Singapore, Malaysia, Southeast Asia) targeting expectant parents with subscription storage models.
• Future Health Biobank: UK-based and internationally operating stem cell bank offering cord blood, cord tissue, and peripheral blood stem cell storage with GMP-accredited processing. Directly comparable as a multi-cell-type consumer bank with international footprint and similar processing/cryopreservation technology stack.
• Stemlife Berhad: Malaysia-based cord blood banking service provider and one of the established players in the region. Directly comparable as a Southeast Asia-based consumer cord blood bank with recurring storage revenue and similar regulatory framework under Malaysian NPRA.
• Cryoviva: Stem cell banking company operating across India and Southeast Asia including Malaysia. Directly comparable as a multi-country cord blood and stem cell bank with a similar expectant-parent target customer and subscription-based storage model.

Broad incumbents

• Cord Blood Registry (CBR): One of the largest U.S.-based cord blood and tissue banking services. Comparable as an established consumer cord blood bank with a multi-cell-type storage offering (cord blood, cord tissue), providing a benchmark for scale, pricing, and unit economics even though it operates in a different geography.
• ViaCord: U.S.-based cord blood and cord tissue banking service owned by Revvity. Comparable as a multi-decade consumer cell bank with subscription storage, sibling/family banking options, and a GMP-grade processing model similar to LongevityBank's positioning.
• Cryo-Cell International: U.S.-listed (OTCQB: CCEL) cord blood and menstrual stem cell banking operator. Comparable as a publicly-traded cell bank with subscription storage revenue and multi-decade customer retention, providing a financial benchmark for the consumer cell banking model.
• CytoMed Therapeutics: NASDAQ-listed (GDTC) parent of LongevityBank and A*STAR spin-out developing allogeneic gamma-delta T cell cancer therapies. Comparable as the upstream clinical/therapeutic platform that consumes the banked cells and sets the strategic direction for LongevityBank.

Regional players

• Smart Cells International: UK-headquartered stem cell bank with a presence in the Middle East and Asia offering cord blood and tissue storage. Comparable as a regional-to-international consumer cell bank with subscription storage, though primarily serving different geographies than LongevityBank.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@thelongevitybank
• Facebookfacebook.com/thelongevitybank
• LinkedInil.linkedin.com/company/thelongevitybank
• Instagraminstagram.com/thelongevitybank
• TikToktiktok.com/@thelongevitybank

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LongevityBank